Clinical Trials
7 trialsNCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT03524235 2024-11-12
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Phase 1 Completed
NCT02168140 2024-02-13
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT01326702 2019-12-16
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02240719 2019-01-04
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
Phase 1 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed